Lars Staal Wegner received his M.D. from the University of Southern Denmark. He is a VP of Business Development at Hengrui Pharmaceuticals, leading global pharmaceutical company committed to promoting a healthier life for humankind through advancements in science. Dr. Wegner brings in deep experience in artificial intelligence and biotechnology finance, business development, and research. He has helped build numerous biotech, diagnostics, and IT companies, sitting on multiple boards. Earlier in his career, he held different roles of increasing responsibility at Bavarian Nordic A/S, including as Vice President of Commercial Affairs, during which time he contributed to developing the company’s Ebola vaccine and different previous roles in Pfizer. Lars Staal Wegner has previously been Chairman (2013-2014), board member (2015-2016) and CEO of Evaxion (2017-2022).
